Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study


Autoria(s): BRITO, Milena Bastos; FERRIANI, Rui Alberto; QUINTANA, Silvana Maria; YAZLLE, Marta Edna Holanda Diogenes; SA, Marcos Felipe Silva de; VIEIRA, Carolina Sales
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background: The effects of etonogestrel (ETG)-releasing contraceptive implant during the immediate postpartum period on maternal safety are unknown. Study design: Forty healthy women exclusively breastfeeding were randomized to receive either ETG-releasing implant 24-48 h after delivery (n=20) or depot medroxyprogesterone acetate (DMPA group; n=20) at the sixth week postpartum. We measured blood pressure, maternal and neonatal weight, body mass index (BMI; kg/m(2)), waist circumference (WC), complete blood count, C-reactive protein, interleukin-6, tumor necrosis factor (TNF-alpha), lipid profile, fasting serum glucose and maintenance of exclusive lactation up to the 12th week postpartum. Results: Decreases in mean maternal weight, BMI (kg/m(2)) and WC were significantly greater in the ETG-releasing implant group than in the MPA group during the first 6 weeks postpartum (-4.64 +/- 2.71 kg vs. -2.6 +/- 2.45 kg mean +/- SD, p=.017; -1.77 +/- 1.06 kg/m(2) vs. -0.97 +/- 0.95 kg/m(2), p=.026; -15.3 +/- 6.72 cm vs. -9.05 +/- 5.84 cm, p=.003, respectively). In addition, total cholesterol and HDL, were lower in DMPA users, and TNF-alpha and leukocytes were higher in DMPA users compared to in the implant group, between 6 and 12 weeks after delivery. The newborns of implant users showed a trend towards gaining more weight, as compared with the infants of the DMPA mothers during the first 6 weeks of life (implant group: +1460.50 +/- 621.34 g vs. DMPA group: +1035.0 +/- 562.43 g, p=.05). The remaining variables, including the duration of exclusive breastfeeding, were similar between the groups. Conclusion: The insertion of ETG-releasing contraceptive implant during the immediate postpartum period was not associated with deleterious maternal clinical effects or with significant maternal metabolic alterations or decreased infant weight gain. (C) 2009 Elsevier Inc. All rights reserved.

Fundacao de Amparo A Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Identificador

CONTRACEPTION, v.80, n.6, p.519-526, 2009

0010-7824

http://producao.usp.br/handle/BDPI/24535

10.1016/j.contraception.2009.05.124

http://dx.doi.org/10.1016/j.contraception.2009.05.124

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

Relação

Contraception

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #Postpartum period #Breastfeeding #Contraceptive #Metabolism #Adverse effects #Etonogestrel #NONMENSTRUAL ADVERSE EVENTS #CLINICAL-TRIALS #CONTRACEPTIVE IMPLANTS #INTRAUTERINE-DEVICE #INTEGRATED ANALYSIS #WOMEN #METABOLISM #LACTATION #MORTALITY #PATTERNS #Obstetrics & Gynecology
Tipo

article

original article

publishedVersion